Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL139849 | 0.70 | MEN1 (0.39) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23896443 | 0.67 | MEN1 (0.37) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3913823 | 0.61 | ALDH1A1 (0.39) | KMT2ACYP3A4ALDH1A1 | |
| SCHEMBL5942990 | 0.61 | MEN1 (0.42) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2119823 | 0.60 | ALDH1A1 (0.38) | KMT2ACYP3A4ALDH1A1ATM | |
| SCHEMBL2119818 | 0.60 | MEN1 (0.40) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL45354 | 0.60 | MEN1 (0.40) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2056786 | 0.60 | MEN1 (0.40) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL95298 | 0.58 | MEN1 (0.44) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL21612148 | 0.56 | MEN1 (0.38) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530687-B2 | Catalysts, methods of making catalysts, and methods of use | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120059182-A1 | Catalysts, Methods of Makting Catalysts, and Methods of Use | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059182-A1 | Catalysts, Methods of Makting Catalysts, and Methods of Use | DKC1, ADCK1, AMD1 | MEN1 919/4885KMT2A 410/4885CYP3A4 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.